Minot Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Minot Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-408	Closed	-$285K	–	208
2022 Q1	$285K	Buy	408 +15	+4%	+$9.49K	0.06%	164
2021 Q4	$248K	Sell	393 -200	-34%	-$123K	0.05%	170
2021 Q3	$359K	Buy	+593	New	+$368K	0.08%	147
2021 Q2	–	Sell	-1,560	Closed	-$738K	–	223
2021 Q1	$738K	Buy	+1,560	New	+$760K	0.19%	103
2020 Q4	–	Sell	-3,050	Closed	-$1.71M	–	165
2020 Q3	$1.71M	Buy	3,050 +723	+31%	+$438K	0.64%	56
2020 Q2	$1.45M	Buy	+2,327	New	+$1.32M	0.72%	52

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Minot Wealth Management's REGN Position: Q2 2022 in Review

Minot Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 408 shares — an estimated $285K sold.

Minot Wealth Management first reported a position in REGN in Q2 2020 and held it in 6 quarters. The position peaked at $1.71M in Q3 2020. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Minot Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Minot Wealth Management sold 408 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $285K.
Minot Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Minot Wealth Management's Regeneron Pharmaceuticals position peaked at $1.71M in Q3 2020.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Minot Wealth Management's 13F filing for Q2 2022, filed 12 Jul 2022.